Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer?

Hanna Eid, Marco Der Van Looij, Etel Institoris, L. Géczi, I. Bodrogi, E. Oláh, M. Bak

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Several prior studies revealed positive p53 expression via immunohistochemistry (IHC) in a large percentage of germ cell testicular cancers (GCTTs). However, the predicting and prognostic value of this protein remains to be defined. Therefore, the aim of our study was to further clarify the role of p53 protein in GCTTs and to look for correlations between its gene expression and other disease parameters, including histological subtype, stage and clinical resistance/sensitivity. Furthermore, we correlated p53 protein expression with that of MDRI gene product protein (Pgp) in order to examine the interrelationship between these two markers. Patients and methods: 77 untreated patients with GCTTs were investigated for their p53 expression using monoclonal antibody and immunohistochemistry in paraffin-embedded specimens. There were 34 patients with stage I, 16 with stage II, 27 with stage III disease. Results: All tumor types, except differentiated teratomas, were immunoreactive for p53 to a various extent ranging from scarcely positive to homogeneously stained tumor cells. Seminomas (S) and embryonal carcinoma (EC) components showed the most positive nuclear staining, p53 expression showed a significant inverse correlation with the stage of disease (P <0.0003). There was a significant positive relationship between p53 immunoreactivity and response to treatment (P = 0.0012), i.e. high levels of p53 expression correlated with clinical sensitivity of the tumors to chemotherapy. We could demonstrate a statistically significant opposite relationship between p53 and Pgp immunoreactivity (P <0.0005). Conclusion: Our results show that p53 status in tumor cells may be a strong determinate of susceptibility to chemotherapy, and that p53 overexpression has a favorable prognosis in terms of response to treatment in GCTTs. Moreover, the findings provide clinical evidence for the presence of significant relationship between p53 and MDR1/Pgp immunoreactivity. They also suggest that patients resistant to chemotherapy and lacking p53 expression might benefit from an alternative appropriately designed chemotherapeutic regimen to achieve further successful treatment in GCTTs.

Original languageEnglish
Pages (from-to)2663-2669
Number of pages7
JournalAnticancer Research
Volume17
Issue number4 A
Publication statusPublished - 1997

Fingerprint

Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
Immunohistochemistry
Drug Therapy
Neoplasms
Proteins
Embryonal Carcinoma
Therapeutics
Seminoma
Teratoma
Paraffin
Monoclonal Antibodies
Staining and Labeling
Gene Expression

Keywords

  • Chemoresistance,
  • Immunohistochemistry
  • p53 expression
  • Testis cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer? / Eid, Hanna; Van Looij, Marco Der; Institoris, Etel; Géczi, L.; Bodrogi, I.; Oláh, E.; Bak, M.

In: Anticancer Research, Vol. 17, No. 4 A, 1997, p. 2663-2669.

Research output: Contribution to journalArticle

@article{0e65d5bc730e4e7486b726c24d3b86b3,
title = "Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer?",
abstract = "Background: Several prior studies revealed positive p53 expression via immunohistochemistry (IHC) in a large percentage of germ cell testicular cancers (GCTTs). However, the predicting and prognostic value of this protein remains to be defined. Therefore, the aim of our study was to further clarify the role of p53 protein in GCTTs and to look for correlations between its gene expression and other disease parameters, including histological subtype, stage and clinical resistance/sensitivity. Furthermore, we correlated p53 protein expression with that of MDRI gene product protein (Pgp) in order to examine the interrelationship between these two markers. Patients and methods: 77 untreated patients with GCTTs were investigated for their p53 expression using monoclonal antibody and immunohistochemistry in paraffin-embedded specimens. There were 34 patients with stage I, 16 with stage II, 27 with stage III disease. Results: All tumor types, except differentiated teratomas, were immunoreactive for p53 to a various extent ranging from scarcely positive to homogeneously stained tumor cells. Seminomas (S) and embryonal carcinoma (EC) components showed the most positive nuclear staining, p53 expression showed a significant inverse correlation with the stage of disease (P <0.0003). There was a significant positive relationship between p53 immunoreactivity and response to treatment (P = 0.0012), i.e. high levels of p53 expression correlated with clinical sensitivity of the tumors to chemotherapy. We could demonstrate a statistically significant opposite relationship between p53 and Pgp immunoreactivity (P <0.0005). Conclusion: Our results show that p53 status in tumor cells may be a strong determinate of susceptibility to chemotherapy, and that p53 overexpression has a favorable prognosis in terms of response to treatment in GCTTs. Moreover, the findings provide clinical evidence for the presence of significant relationship between p53 and MDR1/Pgp immunoreactivity. They also suggest that patients resistant to chemotherapy and lacking p53 expression might benefit from an alternative appropriately designed chemotherapeutic regimen to achieve further successful treatment in GCTTs.",
keywords = "Chemoresistance,, Immunohistochemistry, p53 expression, Testis cancer",
author = "Hanna Eid and {Van Looij}, {Marco Der} and Etel Institoris and L. G{\'e}czi and I. Bodrogi and E. Ol{\'a}h and M. Bak",
year = "1997",
language = "English",
volume = "17",
pages = "2663--2669",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 A",

}

TY - JOUR

T1 - Is p53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancer?

AU - Eid, Hanna

AU - Van Looij, Marco Der

AU - Institoris, Etel

AU - Géczi, L.

AU - Bodrogi, I.

AU - Oláh, E.

AU - Bak, M.

PY - 1997

Y1 - 1997

N2 - Background: Several prior studies revealed positive p53 expression via immunohistochemistry (IHC) in a large percentage of germ cell testicular cancers (GCTTs). However, the predicting and prognostic value of this protein remains to be defined. Therefore, the aim of our study was to further clarify the role of p53 protein in GCTTs and to look for correlations between its gene expression and other disease parameters, including histological subtype, stage and clinical resistance/sensitivity. Furthermore, we correlated p53 protein expression with that of MDRI gene product protein (Pgp) in order to examine the interrelationship between these two markers. Patients and methods: 77 untreated patients with GCTTs were investigated for their p53 expression using monoclonal antibody and immunohistochemistry in paraffin-embedded specimens. There were 34 patients with stage I, 16 with stage II, 27 with stage III disease. Results: All tumor types, except differentiated teratomas, were immunoreactive for p53 to a various extent ranging from scarcely positive to homogeneously stained tumor cells. Seminomas (S) and embryonal carcinoma (EC) components showed the most positive nuclear staining, p53 expression showed a significant inverse correlation with the stage of disease (P <0.0003). There was a significant positive relationship between p53 immunoreactivity and response to treatment (P = 0.0012), i.e. high levels of p53 expression correlated with clinical sensitivity of the tumors to chemotherapy. We could demonstrate a statistically significant opposite relationship between p53 and Pgp immunoreactivity (P <0.0005). Conclusion: Our results show that p53 status in tumor cells may be a strong determinate of susceptibility to chemotherapy, and that p53 overexpression has a favorable prognosis in terms of response to treatment in GCTTs. Moreover, the findings provide clinical evidence for the presence of significant relationship between p53 and MDR1/Pgp immunoreactivity. They also suggest that patients resistant to chemotherapy and lacking p53 expression might benefit from an alternative appropriately designed chemotherapeutic regimen to achieve further successful treatment in GCTTs.

AB - Background: Several prior studies revealed positive p53 expression via immunohistochemistry (IHC) in a large percentage of germ cell testicular cancers (GCTTs). However, the predicting and prognostic value of this protein remains to be defined. Therefore, the aim of our study was to further clarify the role of p53 protein in GCTTs and to look for correlations between its gene expression and other disease parameters, including histological subtype, stage and clinical resistance/sensitivity. Furthermore, we correlated p53 protein expression with that of MDRI gene product protein (Pgp) in order to examine the interrelationship between these two markers. Patients and methods: 77 untreated patients with GCTTs were investigated for their p53 expression using monoclonal antibody and immunohistochemistry in paraffin-embedded specimens. There were 34 patients with stage I, 16 with stage II, 27 with stage III disease. Results: All tumor types, except differentiated teratomas, were immunoreactive for p53 to a various extent ranging from scarcely positive to homogeneously stained tumor cells. Seminomas (S) and embryonal carcinoma (EC) components showed the most positive nuclear staining, p53 expression showed a significant inverse correlation with the stage of disease (P <0.0003). There was a significant positive relationship between p53 immunoreactivity and response to treatment (P = 0.0012), i.e. high levels of p53 expression correlated with clinical sensitivity of the tumors to chemotherapy. We could demonstrate a statistically significant opposite relationship between p53 and Pgp immunoreactivity (P <0.0005). Conclusion: Our results show that p53 status in tumor cells may be a strong determinate of susceptibility to chemotherapy, and that p53 overexpression has a favorable prognosis in terms of response to treatment in GCTTs. Moreover, the findings provide clinical evidence for the presence of significant relationship between p53 and MDR1/Pgp immunoreactivity. They also suggest that patients resistant to chemotherapy and lacking p53 expression might benefit from an alternative appropriately designed chemotherapeutic regimen to achieve further successful treatment in GCTTs.

KW - Chemoresistance,

KW - Immunohistochemistry

KW - p53 expression

KW - Testis cancer

UR - http://www.scopus.com/inward/record.url?scp=0030804718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030804718&partnerID=8YFLogxK

M3 - Article

C2 - 9252698

AN - SCOPUS:0030804718

VL - 17

SP - 2663

EP - 2669

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 A

ER -